KAROLINSKA STROKE UPDATE
13-14 November 2006, Stockholm, Sweden

 


1996

Scientific programme

Dipyridamole with or without aspirin – Implications of The European Stroke Prevention Study nr 2 (ESPS 2)

Chairpersons: Gudrun Boysen (Copenhagen), Jan Edwin Olsson (Linköping)

  • Results of the ESPS 2 study – C. Diener (Essen)  

  • A critical analysis of the role of dipyridamole in stroke prevention – C. Warlow (Edinburgh)

Update on carotid surgery

Chairpersons: Christian Blomstrand (Gothenburg), Jesper Swedenborg (Stockholm)

  • Carotid surgery in asymtomatic stenosis and in moderate symptomatic stenosis –
    C. Warlow     (Edinburgh)  

  • Carotid surgery in symptomatic severe stenosis – N.G. Wahlgren (Stockholm)

Aspirin and anticoagulants in secondary stroke prevention

Chairpersons: Bo Norrving (Lund), Andreas Terent (Uppsala)

  • Update on the role of aspirin and anticoagulants in secondary stroke prevention – Andreas Terent (Uppsala)  

  • Aspirin and anticoagulants in secondary stroke prevention. The risk of haemorrhage – Gudrun Boysen (Copenhagen)

Aspirin and anticoagulants in acute stroke

Chairpersons: Mona Britton (Stockholm), C.E. Söderström (Stockholm)

  • Aspirin and anticoagulants in acute stroke – Peter Sandercock (Edinburgh)  

  • A critical analysis of the role of aspirin and heparin in acute stroke – Trond Dahl (Oslo)

Thrombolysis in acute ischaemic stroke

Chairpersons: Markku Kaste (Helsinki), Vasilios Kostulas (Huddinge)

  • Intravenous thrombolysis studies in stroke– a review – W. Hacke (Heidelberg)  

  • Experiences from local thrombolysis – M. Söderman (Stockholm)  

  • Experiences from intravenous thrombolysis – C. Carlström (Stockholm)  

  • A critical analysis of the role of thrombolysis in acute stroke – L. Candelise (Milan)

Neuroprotective treatment of acute stroke

Chairpersons: K. Lees (Glasgow), G. Hellström (Stockholm) 

  • The GABA approach: Clomethiazole – N.G. Wahlgren (Stockholm)  

  • Lubeluzole – C. Diener  

  • Piracetam – J. DeReuck (Gent)  

  • A critical analysis of the role of neuroprotective drugs in acute stroke – P. Wester (Umeå)

Ticlopidine in stroke prevention

Chairpersons: Hans Göran Hårdemark (Uppsala), Rolf Nyberg-Hansen (Oslo)

  • The role of Ticlopidine in stroke prevention – O. Busse (Minden)
     

  • A critical analysis of the role of ticlopidine in stroke prevention – M. Kaste (Helsinki)

A look into the future

Chairpersons: M. Crisby (Huddinge), P. Wester (Umeå)

  • PBN:s, anti-ICAM and Cytokines – B. Siesjö (Lund)